Clevidipine Butyrate

Clevidipine Butyrate Overview

Clevidipine (INN,[1] trade name Cleviprex) is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. It was approved by the United States Food and Drug Administration on August 1, 2008. Contents 1 Basic chemical and pharmacological properties 1.1 Stereochemistry 2 Dosage and administration 3 Safety information 4 Drug interactions 5 Storage 6 Phase III clinical trial results 7 Reference...

Read more Clevidipine Butyrate Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Clevidipine

Recent Clevidipine Butyrate Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Clevidipine Butyrate

Emulsion: 0.5mg/ml, 125mg/250ml (0.5mg/ml), 25mg/50ml (0.5mg/ml), 25mg/50ml(0.5mg/ml), 50mg/100ml (0.5mg/ml), 50mg/100ml(0.5mg/ml)

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Clevidipine Butyrate or a similar ingredient: (1 result)

CLEVIPREX Clevidipine Butyrate